Bryan, Garnier & Co upgraded shares of AstraZeneca plc (LON:AZN) to a buy rating in a report issued on Monday morning, MarketBeat Ratings reports. Bryan, Garnier & Co currently has GBX 5,380 ($69.48) price objective on the biopharmaceutical company’s stock, up from their previous price objective of GBX 4,700 ($60.70).

AZN has been the subject of several other reports. Liberum Capital restated a buy rating and issued a GBX 4,800 ($61.99) target price on shares of AstraZeneca plc in a report on Tuesday, September 5th. Morgan Stanley restated an overweight rating and issued a GBX 5,600 ($72.32) target price on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 4,550 ($58.76) target price on AstraZeneca plc and gave the stock a neutral rating in a report on Thursday, August 31st. Deutsche Bank AG restated a buy rating on shares of AstraZeneca plc in a report on Monday, May 22nd. Finally, Shore Capital restated a hold rating on shares of AstraZeneca plc in a report on Tuesday, August 29th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of GBX 5,022.91 ($64.87).

Shares of AstraZeneca plc (AZN) opened at 4867.00 on Monday. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The stock’s 50 day moving average is GBX 4,560.14 and its 200-day moving average is GBX 4,882.27. The firm’s market cap is GBX 61.62 billion.

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Upgraded at Bryan, Garnier & Co” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at

The business also recently declared a dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, August 10th were given a GBX 68.90 ($0.89) dividend. This represents a yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.

In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction dated Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with's FREE daily email newsletter.